Travere Therapeutics (TVTX) stock price, revenue, and financials

Travere Therapeutics market cap is $1.9 b, and annual revenue was $198.32 m in FY 2020

$1.9 B

TVTX Mkt cap, 31-Dec-2021

$47.4 M

Travere Therapeutics Revenue Q1, 2021
Travere Therapeutics Gross profit (Q1, 2021)45.8 M
Travere Therapeutics Gross profit margin (Q1, 2021), %96.5%
Travere Therapeutics Net income (Q1, 2021)-53.9 M
Travere Therapeutics EBIT (Q1, 2021)-47.5 M
Travere Therapeutics Cash, 31-Mar-2021148.2 M
Travere Therapeutics EV1.9 B
Get notified regarding key financial metrics and revenue changes at Travere TherapeuticsLearn more
Banner background

Travere Therapeutics Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

28.2m99.9m133.6m154.9m164.2m175.3m198.3m

Revenue growth, %

254%34%

Cost of goods sold

571.0k2.2m4.6m3.6m5.5m5.2m6.1m

Gross profit

27.6m97.7m129.0m151.3m158.7m170.1m192.2m

Gross profit Margin, %

98%98%97%98%97%97%97%

R&D expense

524.0k7.1m47.8m50.4m70.9m78.2m123.8m141.0m131.8m

General and administrative expense

1.3m17.7m59.6m79.5m92.8m101.3m103.7m129.0m135.8m

Operating expense total

1.8m24.8m107.4m130.0m163.7m205.1m238.8m307.5m368.4m

EBIT

(24.0m)(79.8m)(50.7m)(58.2m)(53.8m)(80.0m)(137.4m)(176.2m)

EBIT margin, %

(283%)(51%)(44%)(35%)(49%)(78%)(89%)

Interest expense

105.9k46.3k7.4m7.7m759.0k1.2m5.5m

Interest income

21.8k10.1m5.0m

Pre tax profit

(33.7m)(113.4m)105.5m(57.6m)(58.4m)(101.9m)(146.4m)(188.8m)

Income tax expense

(1.9k)(75.8k)2.5m11.8m9.7m1.4m811.0k(21.0k)(19.4m)

Net Income

(30.3m)(33.8m)(110.9m)117.2m(47.9m)(59.7m)(102.7m)(146.4m)(169.4m)

Quarterly

USDQ2, 2012Q3, 2012Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

27.9k5.7m8.3m17.4m24.1m29.0m33.3m33.9m33.6m38.8m40.3m38.4m41.3m40.7m39.6m44.7m44.4m47.8m48.4m51.1m47.4m

Cost of goods sold

900.01.2m197.4k274.4k637.0k513.0k757.0k1.0m1.6m709.0k797.0k925.0k1.6m1.2m1.1m1.0m979.0k1.5m1.5m1.2m1.6m

Gross profit

27.0k4.5m8.2m17.1m23.4m28.3m32.3m32.4m32.9m38.0m39.4m36.8m40.2m39.6m38.6m43.7m42.9m46.9m50.0m45.8m

Gross profit Margin, %

97%79%98%98%97%97%97%95%98%98%98%96%97%97%97%98%97%97%98%97%

R&D expense

108.7k605.2k1.4m6.9m13.7m13.0m10.3m10.6m14.1m14.7m17.7m18.4m20.9m19.5m19.6m24.6m34.5m32.4m33.4m37.9m33.2m30.2m30.8m32.3m47.9m

General and administrative expense

3.0k3.0k3.0k412.6k2.9m812.1k10.1m11.3m18.6m14.9m19.7m22.3m19.1m23.2m23.8m23.1m28.8m24.9m26.5m25.1m26.1m32.7m39.0m29.8m33.1m35.0m32.0m36.8m

Operating expense total

3.0k3.0k3.0k521.4k3.5m2.2m17.0m25.0m31.6m25.2m30.3m48.5m36.5m43.7m52.7m47.3m51.6m50.0m54.7m61.7m75.2m76.8m80.3m77.3m63.4m70.0m69.4m93.3m

EBIT

(3.5k)(2.3m)(5.1m)(5.2m)(17.0m)(20.5m)(23.4m)(8.1m)(6.8m)(20.5m)(8.2m)(11.4m)(20.4m)(14.4m)(13.6m)(10.6m)(17.9m)(21.6m)(35.6m)(38.2m)(36.5m)(34.4m)(15.1m)(23.1m)(19.4m)(47.5m)

EBIT margin, %

(60759%)(357%)(281%)(47%)(28%)(28%)(34%)(60%)(43%)(35%)(26%)(47%)(52%)(87%)(97%)(82%)(78%)(32%)(48%)(38%)(100%)

Interest expense

500.0500.041.6k2.2m2.6m3.8m2.9m695.0k163.0k147.0k299.0k132.0k658.0k65.0k358.0k199.0k1.1m2.8m2.6m2.5m2.0m1.3m1.1m409.0k

Interest income

Pre tax profit

(3.5k)(3.5k)(70.6m)6.0m(19.6m)(366.2k)(25.5m)144.3m6.1m(20.8m)(30.6m)(13.2m)(15.2m)(19.0m)(18.1m)(22.2m)(54.1m)(40.6m)(38.6m)(37.0m)(18.2m)(26.0m)(22.5m)(53.6m)

Income tax expense

65.4k(2.5m)(40.0m)15.0k(38.8m)(5.1m)(7.4m)6.5m(2.1m)(1.9m)(1.2m)200.0k200.0k400.0k401.0k100.0k(523.0k)(19.0m)65.0k23.0k313.0k

Net Income

(3.5k)(3.5k)(3.5k)(4.7m)(5.0m)(10.9m)(70.6m)8.5m(19.6m)39.7m(25.5m)105.6m11.2m(13.4m)(37.1m)(11.1m)(13.2m)(17.8m)(18.4m)(22.3m)(54.5m)(41.0m)(38.7m)(36.5m)808.0k(26.1m)(22.5m)(53.9m)

Travere Therapeutics Balance Sheet

Annual

Quarterly

USDQ2, 2012Q3, 2012Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

3.9k3.9k3.9k2.5m286.5k13.4m3.7m39.9m25.9m120.2m127.7m140.6m23.3m21.2m23.9m41.9m89.3m99.0m61.1m89.3m154.8m69.8m75.7m65.2m67.0m237.2m200.5m148.2m

Accounts Receivable

28.8k1.6m4.7m8.2m11.5m13.5m13.4m16.6m15.0m15.4m13.3m14.5m13.0m12.3m13.5m12.7m16.8m18.1m14.1m15.0m

Prepaid Expenses

134.5k117.9k480.6k1.0m1.9m2.3m1.1m1.4m2.0m3.1m3.4m3.6m3.2m2.3m2.6m2.0m2.9m3.5m8.2m9.2m8.6m5.3m7.7m5.5m6.7m

Inventories

349.1k496.7k683.6k1.7m2.0m2.7m3.2m2.7m3.3m4.8m4.4m4.3m5.1m5.4m5.1m5.6m5.1m5.3m6.6m6.3m7.3m7.2m

Current Assets

3.9k2.6m404.4k16.8m6.4m53.4m45.4m233.5m244.7m300.0m297.7m300.2m342.6m322.4m319.7m325.3m286.8m278.9m503.0m475.5m457.0m439.7m406.6m505.6m497.7m565.0m

PP&E

28.4k28.6k38.4k280.4k511.3k633.2k618.6k509.0k478.0k417.0k381.0k382.0k2.4m2.5m2.7m3.0m3.5m3.3m3.0m3.0m2.9m2.6m2.9m5.7m11.7m

Goodwill

1.0m935.9k935.9k935.9k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k936.0k

Total Assets

3.9k5.0m2.7m21.4m94.0m155.5m145.9m416.0m425.1m511.6m507.1m534.0m532.4m510.4m507.1m520.5m500.8m491.1m716.2m667.7m647.6m613.8m573.1m678.7m692.2m764.0m

Accounts Payable

484.7k1.4m1.7m5.7m10.6m11.3m5.9m4.8m4.9m4.6m6.3m3.1m4.7m9.1m7.4m9.4m7.8m9.3m7.6m12.5m13.8m10.0m10.2m9.4m15.0m

Short-term debt

25.0m31.3m39.8m41.1m45.4m22.4m22.5m

Current Liabilities

68.0k1.6m11.1m27.2m113.4m48.0m49.1m102.2m172.4m101.9m66.6m80.1m86.0m76.6m79.6m83.9m56.5m103.5m99.9m104.1m90.6m88.0m68.1m69.9m75.4m85.0m

Long-term debt

40.2m40.8m192.8m197.5m199.9m202.4m207.4m210.0m212.7m218.1m

Total Debt

25.0m62.6m39.8m40.2m40.8m41.1m45.4m215.1m220.0m199.9m202.4m207.4m210.0m212.7m218.1m

Total Liabilities

8.5m129.4m154.5m156.1m247.4m274.4m220.6m187.9m219.6m224.8m209.4m211.3m216.0m201.3m203.2m397.1m382.0m370.5m367.9m347.3m360.0m390.8m401.4m

Common Stock

1.2k1.2k1.8k2.5k2.7k2.7k3.5k3.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k4.0k5.0k5.0k6.0k

Preferred Stock

Additional Paid-in Capital

66.9m79.0k34.8m34.9m48.6m105.4m133.4m138.4m310.2m318.3m353.8m373.3m381.7m412.3m430.4m438.6m465.1m486.7m497.2m582.7m596.6m626.0m631.0m642.9m758.9m765.3m1.0b

Retained Earnings

(131.8k)(143.1k)(149.1m)(142.7m)(168.3m)(62.7m)(53.9m)(67.3m)(104.5m)(129.0m)(142.2m)(160.0m)(185.7m)(208.0m)(262.6m)(311.0m)(349.7m)(386.2m)(415.6m)(441.7m)(464.3m)(639.7m)

Total Equity

(61.8k)(64.1k)(3.6m)(8.5m)(5.8m)(35.4m)1.1m(10.2m)168.6m150.8m291.0m319.2m314.4m307.6m300.9m295.8m304.5m283.8m288.0m319.1m285.7m277.1m246.0m225.7m318.6m301.4m362.7m

Debt to Equity Ratio

-1.8 x37.3 x-3.9 x0.2 x0.3 x0.2 x

Debt to Assets Ratio

0.7 x0.3 x0.3 x0.1 x0.1 x0.1 x

Financial Leverage

-0.1 x-1.4 x-0.3 x-3.7 x-2.7 x145.8 x-14.3 x2.5 x2.8 x1.8 x1.6 x1.7 x1.7 x1.7 x1.7 x1.7 x1.8 x1.7 x2.2 x2.3 x2.3 x2.5 x2.5 x2.1 x2.3 x2.1 x

Travere Therapeutics Cash Flow

Quarterly

USDQ2, 2012Q3, 2012Q2, 2013Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(3.5k)(3.5k)(7.0k)(4.7m)(9.8m)(20.7m)(70.6m)(62.1m)(81.7m)39.7m14.1m119.7m11.2m(2.2m)(39.3m)(11.1m)(24.3m)(42.1m)(18.4m)(40.7m)(95.2m)(41.0m)(79.7m)(116.2m)808.0k(25.3m)(47.8m)(53.9m)

Depreciation and Amortization

52.2k105.3k159.1k127.2k1.7m3.5m1.8m5.5m9.4m3.9m7.9m12.0m4.3m8.7m13.3m4.3m9.0m13.8m4.9m9.7m15.1m5.7m11.5m17.9m6.1m

Accounts Receivable

(28.8k)(1.6m)(4.7m)(203.1k)(3.5m)(5.5m)(927.0k)(4.1m)(2.5m)3.1m4.7m4.1m886.0k1.4m1.3m40.0k(2.4m)(4.0m)(61.0k)4.0m3.2m2.9m

Inventories

900.021.3k(165.6k)(352.7k)(640.0k)(1.1m)(302.0k)(174.0k)(712.0k)(549.0k)(212.0k)(319.0k)(593.0k)(433.0k)(1.4m)(170.0k)918.0k947.0k(958.0k)(875.0k)(3.8m)(63.0k)

Accounts Payable

1.0k(2.4m)312.0k(313.4k)1.6m6.5m13.8m(3.2m)(4.4m)(852.0k)(3.6m)650.0k3.3m(4.8m)(3.5m)425.0k(9.3m)(2.8m)6.8m(3.1m)6.3m5.0m(16.6m)(16.4m)(10.2m)(4.4m)

Cash From Operating Activities

(9.0)(4.6m)(6.8m)(9.4m)(9.8m)(21.3m)(36.8m)(7.3m)566.0k2.0m(3.6m)423.0k5.2m(2.8m)2.6m8.3m(14.7m)(17.5m)(21.4m)(20.5m)(39.6m)(53.7m)(29.2m)(35.6m)(28.9m)(26.5m)

Purchases of PP&E

(6.8k)(9.7k)(22.2k)(166.1k)(423.5k)(581.2k)(24.8k)(29.0k)(35.0k)(24.0k)(24.0k)(61.0k)(838.0k)(1.1m)(1.4m)(39.0k)(601.0k)(727.0k)(19.0k)(21.0k)(286.0k)(208.0k)(518.0k)(2.9m)(4.5m)

Cash From Investing Activities

(1.3m)(1.3m)(6.7m)(31.1m)(37.2m)(39.2m)(29.9m)(31.3m)19.9m(9.8m)(14.0m)(20.2m)4.1m47.9m45.7m(20.9m)7.1m(154.5m)(11.4m)13.8m18.3m39.6m107.4m64.2m(105.7m)

Short-term Borrowings

(45.0m)

Long-term Borrowings

(13.2k)(13.2k)(31.9k)(500.0k)(750.0k)(500.0k)(750.0k)(500.0k)(41.0m)

Cash From Financing Activities

8.4m8.4m29.5m38.6m92.3m95.9m139.2m140.2m100.5m(926.0k)(2.8m)1.2m(361.0k)(1.8m)4.1m(2.7m)383.0k231.3m(1.1m)(1.4m)(2.2m)(5.8m)103.0m102.7m195.8m

Net Change in Cash

(9.0)2.5m275.1k13.4m(2.3m)33.9m19.9m102.0m109.5m122.4m(14.5m)(16.6m)(13.9m)869.0k48.3m58.0m(38.3m)(10.1m)55.4m(33.0m)(27.2m)(37.7m)4.6m174.7m138.0m63.5m

Interest Paid

28.3k28.3k28.3k1.8m3.1m2.5m4.8m5.0m

Income Taxes Paid

Travere Therapeutics Ratios

USDQ2, 2012

Travere Therapeutics Employee Rating

4.322 votes
Culture & Values
4.2
Work/Life Balance
4
Senior Management
4
Salary & Benefits
3.9
Career Opportunities
4
Source